Global Human Vascular Endothelial Growth Factor Antibody Market Size, Share, and Trends Analysis Report, By Type (Avastin, Cometriq, Eylea, Jetrea, Cyramza, Macugen, Lucentis, and Others), By Application (Cancer, Ophthalmology, and Others) Forecast (2022-2028)

The global human vascular endothelial growth factor (VEGF) antibody market is anticipated to grow at a significant CAGR of 10.1% during the forecast period (2022-2028). A Human VEGF antibody is a signal protein that helps in the formation of new blood vessels through a process known as angiogenesis. It is used to create new blood vessels during embryonic development, new blood vessels after injury, muscle following exercise, and new vessels to bypass blocked vessels. The human VEGF antibody market is growing due to the rising prevalence of cancer patients globally. According to the World Health Organization, cancer is a leading cause of death globally, accounting for around 10 million deaths in 2020, or around one in every sixth death.

The rising macular degeneration cases globally are also driving the demand for human VEGF antibodies. According to Macular Degeneration Research by BrightFocus Foundation in July 2021, macular degeneration is a leading cause of vision loss in Americans of age 60 years and above. Around 196 million people are living with macular degeneration globally and it will increase to 288 million by 2040. Additionally, improved healthcare infrastructure, several clinical trials along with huge investment by major market players for improvement in new drug therapies is also driving the demand for the global human VEGF antibody market.

The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new drug launches, to stay competitive in the market. For instance-

• In January 2022, Compass Therapeutics, Inc. received the USFDA clearance of investigational new drug application for a phase-2 study of CTX-009, a bispecific antibody that simultaneously targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor-A.
• In January 2022, the USFDA approved Faricimab, a bispecific monoclonal antibody drug to target two distinct pathways, Ang-2 and VEGF-A, that often cause retinal disease that may lead to vision loss.
• In January 2022, Genentech, Inc. announced the launch of Vabysmo for the treatment of people with wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema in the US market.
• In October 2021, F. Hoffmann-La Roche Ltd. received the USFDA approval for Susvimo, a first-of-its-kind therapeutic approach for the treatment of neovascular or wet age-related macular degeneration.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Bayer AG, Novartis AG, Regeneron Pharmaceuticals Inc., Eli Lilly and Co., Genentech, Inc., and Ceres Oncology Pty Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Human Vascular Endothelial Growth Factor Antibody Market Report by Segment

By Type

• Avastin
• Cometriq
• Eylea
• Jetrea
• Cyramza
• Macugen
• Lucentis
• Others

By Application

• Cancer
• Ophthalmology
• Others

Global Human Vascular Endothelial Growth Factor Antibody Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa